Teva Reports Full Year 2015 and Fourth Quarter Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Mizuho Securities Cuts Price Target on Teva Pharma (TEVA) Following Slight 4Q EPS Miss
February 12, 2016 7:33 AM ESTMizuho Securities reiterated a Buy rating on Teva Pharma (NYSE: TEVA), and cut the price target to $78.00 (from $79.00), following the company's 4Q earnings report. Teva reported a modest beat on revenues of $4.88B relative to consensus estimates of $4.84B, but missed bottom-line by a... More
Teva Pharma (TEVA) Misses Q4 EPS by 1c
February 11, 2016 7:04 AM ESTTeva Pharma (NYSE: TEVA) reported Q4 EPS of $1.28, $0.01 worse than the analyst estimate of $1.29. Revenue for the quarter came in at $4.88 billion versus the consensus estimate of $4.83 billion.
Non-GAAP EPS adjusted to exclude Dec 15 equity offerings was $1.32.
GUIDANCE:
Teva Pharma sees Q1 2016 EPS of $1.32-$1.36, versus the consensus of $1.21. Teva Pharma sees Q1 2016 revenue of $4.7-4.9 billion, versus the consensus of $4.92 billion.
"2015... More
